Table 1 Patient and treatment characteristics.
Variable | Number of patients (%) |
|---|---|
Age, median (range) | 70 (48–90) |
Gender | |
Male | 37 (79%) |
Female | 10 (21%) |
Cause of underlying chronic liver disease | |
Alcohol | 22 (47%) |
Hepatitis B | 13 (28%) |
Hepatitis C | 22 (47%) |
Non-alcoholic steatohepatitis | 2 (4%) |
Child Pugh score | |
A5 | 27 (57%) |
A6 | 11 (24%) |
B7 | 9 (19%) |
ALBI grade | |
1 | 20 (43%) |
2 | 24 (51%) |
3 | 3 (6%) |
HCC thrombus | |
Absent | 21 (45%) |
Present | 26 (55%) |
Previous treatment | |
Any | 23 (49%) |
None | 24 (51%) |
In-field tumor response at 3 months | |
Stable disease | 21 (57%) |
Partial response | 15 (41%) |
Complete response | 1 (2%) |
Baseline laboratory values, median (range) | |
Bilirubin, μmol/L | 14 (6–42) |
Albumin, g/L | 38 (23–47) |
Platelet, ×109/L | 117 (55-366) |
Gross tumor volume, mL, median (range) | 96.8 (1.3–1385.1) |
Prescription dose, Gy, median (range) | 33 (30–54) |
Liver mean dose, Gy, median (range) | 15.3 (4.3–18.2) |
D800cc, Gy, median (range) | 7.4 (0–25.3) |
Veff, %, median (range) | 39 (9–60) |
Liver volume, mL, median (range) | 1231.4 (750–3080.7) |
